TL;DR
Differentiating between past infections of mosquito-borne viruses like Dengue, Zika, and West Nile is notoriously difficult due to antibody cross-reactivity. This paper demonstrates that targeting antibodies against the viral premembrane (prM) protein using a Western blot assay provides a highly specific marker to distinguish between four major flavivirus serocomplexes, successfully untangling complex patient immune histories where multiple viruses co-circulate.
What Problem Does This Paper Address?
Flaviviruses—a family of mosquito-borne viruses including Dengue (DENV), Zika (ZIKV), West Nile (WNV), and Yellow Fever (YFV)—are a massive global health threat. To track outbreaks, evaluate vaccine efficacy, and understand how prior immunity to one virus affects infection by another, public health officials rely on serosurveillance (testing blood for specific antibodies).
However, flaviviruses are structurally very similar. The major target for standard antibody tests is the viral Envelope (E) protein. Because the E protein is highly conserved across the flavivirus family, a patient who had Dengue will often test positive for Zika on an E-protein test due to "cross-reactivity."
The current gold standard to get around this is the Plaque Reduction Neutralization Test (PRNT). But PRNT is slow (takes nearly a week), requires live viruses and high biocontainment, and crucially, it struggles to interpret results if a patient has been infected by multiple different flaviviruses over their lifetime. The authors needed a fast, highly specific serological test that could look at a single drop of blood and definitively say: "This person had Dengue and Zika, but not West Nile."
Methods
The researchers developed a multiplexed Western blot analysis. Instead of just looking at the cross-reactive Envelope (E) protein, they looked at patient antibody responses to three different viral proteins simultaneously: the Envelope (E) protein, Nonstructural protein 1 (NS1), and the premembrane (prM) protein.
They grew cells infected with six different flaviviruses (DENV1, DENV2, DENV4, ZIKV, WNV, and the YFV vaccine strain), lysed them, and ran the viral proteins on a gel. They then exposed these viral proteins to human serum samples. By observing which specific viral proteins the human antibodies bound to, they could map the patient's exposure history. The core novelty is the identification and validation of the anti-prM antibody as a highly specific marker that does not cross-react between the four different viral serocomplexes.
Datasets
The study utilized several panels of human and non-human primate serum/plasma:
- Control Panels (189 samples): Samples with well-documented, laboratory-confirmed (via RT-PCR or PRNT) infection histories. This included primary and secondary Dengue, primary Zika, Dengue+Zika combinations, West Nile, and Yellow Fever vaccinees.
- Surveillance Test Panels (98 samples):
- 50 samples from a fever surveillance program in the Philippines (2018-2019).
- 48 samples from suspected Zika cases in Salvador, Brazil (2015-2016).
Key Insights and Ideas
- The E-protein is a diagnostic dead-end for specificity: The study visually confirmed that anti-E antibodies cross-react massively. Almost every positive sample bound to the E-proteins of all six tested viruses, regardless of which specific virus the patient actually had.
- prM is the "sweet spot" for serosurveillance: Antibodies targeting the premembrane (prM) protein proved to be remarkably specific to the virus's serocomplex. If a patient only had Zika, their anti-prM antibodies only bound to the Zika prM band on the blot.
- Untangling overlapping epidemics: In regions like Brazil, a single person might have had Dengue, caught Zika during the 2015 outbreak, and received a Yellow Fever vaccine. Standard neutralization tests get overwhelmed by this multitypic response. This prM-based Western blot can clearly display distinct, separate bands for DENV, ZIKV, and YFV in a single patient sample, effectively reading their viral immunological history like a barcode.
Key Results
- High Accuracy: The anti-prM antibody marker achieved excellent overall sensitivity and specificity for differentiating the four serocomplexes:
- DENV: 91.7% sensitivity / 96.4% specificity
- ZIKV: 91.7% sensitivity / 99.2% specificity
- WNV: 88.9% sensitivity / 98.3% specificity
- YFV: 91.3% sensitivity / 92.5% specificity
- Real-world Application (Philippines): Testing the 50 unknown samples from the Philippines revealed a 70% Dengue exposure rate and a 10% Zika exposure rate. This 10% ZIKV rate perfectly aligns with epidemiological suspicions of low-level, sustained Zika circulation in Southeast Asia.
- Real-world Application (Brazil): Testing the 48 Brazilian samples showed 100% had previous Dengue, 52.1% had Zika, and 60.4% had Yellow Fever (likely from the country's vaccination program).
- Efficiency: The assay takes about 18 hours (compared to 5-6 days for PRNT) and requires only 5 µL of sample (compared to 128 µL for PRNT).
Limitations and Future Work
- Sample Size and Duration: The control panels of well-documented infections were relatively small. Furthermore, while they tested samples up to 31 years post-Dengue infection, they need to verify if anti-prM antibodies persist for decades following Zika or West Nile infections.
- Vaccine vs. Natural Infection: Because live-attenuated vaccines (like the YF-17D Yellow Fever vaccine) produce the actual viral proteins in the body, this assay cannot distinguish between someone who caught wild Yellow Fever and someone who was vaccinated against it.
- Future Directions: The authors suggest formatting this Western blot into simple, inexpensive diagnostic strips (similar to early HIV tests) for regional labs. They also plan to use it in retrospective studies—such as examining pregnant women from the Zika outbreak—to see how prior immunity to Dengue or Yellow Fever might have influenced congenital Zika syndrome outcomes.
Summary updated